Preparation and Evaluation of Zafirlukast Compression Coated Tablets for Chronotherapeutic Drug Delivery

M. S. Neeharika¹ and B. Jeevana Jyothi¹

¹Department of Pharmaceutics, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women’s University), Tirupati – 517 502, Andhra Pradesh, India.

Authors’ contributions
This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i32B31757
Editor(s):
(1) Dr. Rafik Karaman, Al-Quds University, Palestine.
Reviewers:
(1) Aysha Rehman, University of Gujrat, Pakistan.
(2) Anusha. N, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India.
Complete Peer review History: http://www.sdiarticle4.com/review-history/69874

ABSTRACT

The objective of the present study was to formulate and evaluate an oral, time-controlled drug delivery system of Zafirlukast. Zafirlukast belongs to BCS class II drugs as it has poor aqueous solubility and good permeability. Hence an attempt has been made to improve its aqueous solubility by solid dispersion technique so that its dissolution, bioavailability, and therapeutic effect can be optimized. The optimized solid dispersion was then formulated into a chronotherapeutic drug delivery system by compression coating technology. FT-IR study revealed that there was no chemical interaction between the drug and polymers used. Tablets were prepared by direct compression method using different super disintegrants and then followed by compression coating using natural polymers. Pre-compression and post-compression parameters complied with the Pharmacopoeia limit for the tablets. In vitro release studies were performed and the results indicated the formulation Z9F9 to be the optimized formulation.

Keywords: Zafirlukast; FTIR studies; solid dispersion; compression-coating technique; In vitro drug release studies.

*Corresponding author: E-mail: satyaneharika@gmail.com;
1. INTRODUCTION

Oral drug delivery has been known for decades as the most widely utilized route of administration among all the routes that have been employed for the systemic delivery of drug via various pharmaceutical products of different dosage forms. The reasons that the oral route achieved such popularity may be in part attributed to its ease of administration [1]. The goal in drug delivery research is to develop formulations to meet therapeutic needs relating to particular pathological conditions. Research in the chronopharmacological field has demonstrated the importance of biological rhythms in drug therapy, and this brought a new approach to development of drug delivery system [2].

Chronotherapy considers a person's biological rhythms in determining the timing and amount of medication to optimize a drug's desired effects and minimize the undesired ones [3]. Coordinating biological rhythms with medical treatment is known as chronotherapy, which allows for appropriate dosing of actives at the most suitable times of the day, thus improving efficacy and reducing undesirable side effects [4].

The potential benefits of chronotherapeutics have been demonstrated in the management of a number of diseases like hypertension, asthma, allergic rhinitis, peptic ulcer disease, rheumatoid arthritis and related disorders which follow body's circadian rhythm. Administration of the most appropriate drug in the form of pulsatile delivery system wherein the delivery device is capable of releasing the drug after predetermined lag time could offer a more effective therapy providing maximum drug concentration at maximum intensity of disease condition. [5,6]

Pulsatile drug delivery denotes the capability of a controlled release preparation to deliver the drug at varying rates from very low to high over a desirable time. Out of various timed release formulations available, compression-coated tablets gained wide attention. Compression-coated tablets (CCT's) are composed of an inner core that contains an active pharmaceutical ingredient surrounded by an outer layer that slowly dissolves or disintegrates to make a lag time of drug release. A timed-release formulation could allow drug release and a greater plasma drug concentration at the point in the circadian cycle when clinical signs develop or increase. [7]

Asthma is a chronic inflammatory disease of the airways, characterized by hyper responsiveness to a variety of stimuli. The role of circadian rhythms in the pathogenesis and treatment of asthma indicates that airway resistance increases progressively at night in asthmatic patients. Chronotherapy for asthma is aimed at getting maximal effect from bronchodilator medications during early morning hours [8].

The objective of the present study was to formulate and evaluate an oral, time-controlled drug delivery system of Zafirlukast (an oral leukotriene receptor antagonist that blocks the action of the cysteiny1 leukotrienes on the CysLT1 receptors which is chemically designated as cyclopropetyl N-[3-[(2-methoxy-4-[(2-methylphenyl) sulfonyl carbamoyl] phenyl] methyl]-1-methylindol-5-yl]carbamate) [9] based on chronopharmaceutical approach by the press (compression) coating technology using natural polymers for the treatment of nocturnal asthma. Zafirlukast, a BCS class II drug has poor aqueous solubility and good permeability. Hence, enhancement of its aqueous solubility has been attempted by means of solid dispersion technique [10].

2. MATERIALS AND METHODS

2.1 Materials

Zafirlukast was purchased from BMR Chemicals, Hyderabad. PEG 15000 was purchased from Himedia Laboratories Pvt. Ltd., Mumbai, microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, talc (purchased from S.D.Fine chemicals, Mumbai), magnesium stearate (from Central drug house (p) Ltd, Bombay), sodium lauryl sulphate (from Rankem Laboratories, Hyderabad), xanthan gum, locust bean gum, tamarind gum and dammar gum (from N.R.Chem., Mumbai) and all other ingredients used were of pharmaceutical grade.

2.2 Methods

2.2.1 Drug-excipient compatibility study (Fourier transform infra-red spectroscopy) [11]

FT-IR spectra (400-4400cm\(^{-1}\)) were obtained on a Perkin-Elmer FT-IR spectrophotometer with a resolution of 4 cm\(^{-1}\). KBr pellets were prepared gently by mixing the 1 mg sample with 100 mg Potassium bromide.
2.2.2 Preparation of Solid Dispersions using PEG 15000 [12,13]

Solid dispersions of Zafirlukast via PEGylation with PEG 15000 in different weight ratios (1:0.5, 1:1, 1:1.5, 1:2, 1:2.5) were prepared by physical mixing, kneading, and solvent evaporation methods as shown in Table: 1.

a) **Physical mixtures:** Accurately weighed quantities of drug and polymer were taken in a glass mortar and mixed thoroughly. The resultant mixture was passed through sieve number 100 and was stored in a desiccator for complete removal of moisture.

b) **Kneading method:** The weighed quantities of drug and polymer at different ratios were taken in a mortar and triturated with a small volume of acetone. The obtained mass was kneaded for 45 min, dried in a desiccator for 48 hours. The dried product was pulverized, sifted through sieve number 100, and stored in a well-closed container, and kept in a desiccator.

c) **Solvent evaporation method:** Drug and polymer were mixed in different ratios in a mortar. Acetone was added proportionately with constant and continuous stirring until the mixture was completely dissolved. Acetone was evaporated under constant stirring and resultant solid dispersions were crushed, pulverized, and sifted through 100 mesh.

2.2.3 Formulation of Core Tablets of Zafirlukast by Direct Compression

The inner core/immediate-release tablets containing Zafirlukast were prepared by the direct compression method. As per the formulation variables shown in the Table: 2, the solid dispersions of Zafirlukast, microcrystalline cellulose and super disintegrant were dry blended for 15 min followed by the addition of talc and magnesium stearate. The mixtures were then further blended for 5 min. The resultant powder blends were then evaluated for flow properties like the angle of repose, bulk density, tapped density, Carr’s index, and Hausner’s ratio and finally compressed using a single punch CADMACH machine at a compression pressure of around 5-6 kg/cm² to obtain tablets of 6.0mm diameter and weighing 100mg each. The tablets were packed in aluminum foil, wrapped with brown paper.

2.2.4 Preparation of Compression-Coated Tablets of Zafirlukast

The press coated tablets of Zafirlukast (Z9F1-Z9F9) were prepared by compression coating of the optimized core tablet formulation (ZF9) with outer barrier layers of 400mg each having different compositions of polymers like xanthan gum, tamarind gum, locust bean gum, and dammar gum, the formulae of which are mentioned in the Table:3.

---

**Table 1. Preparation of solid dispersions using PEG 15000**

| METHOD          | Drug: Polymer Ratio | Drug (mg) | Polymer PEG 15000 (mg) |
|-----------------|---------------------|-----------|------------------------|
| **Physical Mixing** | 1:0.5 | 100 | 50 (PF1)   |
|                 | 1:1   | 100 | 100 (PF2)  |
|                 | 1:1.5 | 100 | 150 (PF3)  |
|                 | 1:2   | 100 | 200 (PF4)  |
|                 | 1:2.5 | 100 | 250 (PF5)  |
| **Kneading Method** | 1:0.5 | 100 | 50 (PF6)   |
|                 | 1:1   | 100 | 100 (PF7)  |
|                 | 1:1.5 | 100 | 150 (PF8)  |
|                 | 1:2   | 100 | 200 (PF9)  |
|                 | 1:2.5 | 100 | 250 (PF10) |
| **Solvent Evaporation Method** | 1:0.5 | 100 | 50 (PF11)  |
|                 | 1:1   | 100 | 100 (PF12) |
|                 | 1:1.5 | 100 | 150 (PF13) |
|                 | 1:2   | 100 | 200 (PF14) |
|                 | 1:2.5 | 100 | 250 (PF15) |

---
Table 2. Formulation table for core tablets of Zafirlukast

| S.NO. | Ingredients                                      | ZF1 | ZF2 | ZF3 | ZF4 | ZF5 | ZF6 | ZF7 | ZF8 | ZF9 |
|-------|--------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 1.    | Zaf:PEG 15000 (1:2.5) solid dispersion equivalent to 10 mg Zafirlukast | 38  | 38  | 38  | 38  | 38  | 38  | 38  | 38  | 38  |
| 2.    | Microcrystalline cellulose                        | 57  | 57  | 57  | 55  | 55  | 55  | 53  | 53  | 53  |
| 3.    | Croscarmellose sodium                             | 2   | --  | --  | 4   | --  | --  | 6   | --  | --  |
| 4.    | Sodium starch glycolate                           | --  | 2   | --  | --  | 4   | --  | 6   | --  | --  |
| 5.    | Ludiflash                                        | --  | 2   | --  | --  | 4   | --  | --  | --  | 6   |
| 6.    | Magnesium stearate                                | 2   | 2   | 2   | 2   | 2   | 2   | 2   | 2   | 2   |
| 7.    | Talc                                             | 1   | 1   | 1   | 1   | 1   | 1   | 1   | 1   | 1   |
| 8.    | Erythrosin red                                    | Qs  | qs  | qs  | qs  | Qs  | qs  | qs  | qs  | qs  |
|       | Total (mg)                                       | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |

Table 3. Formulation table for compression-coated tablets of Zafirlukast

| Ingredients               | Z1F9 | Z2F9 | Z3F9 | Z4F9 | Z5F9 | Z6F9 | Z7F9 | Z8F9 | Z9F9 |
|---------------------------|------|------|------|------|------|------|------|------|------|
| Core                      | 100  | 100  | 100  | 100  | 100  | 100  | 100  | 100  | 100  |
| Xanthan gum               | 200  | 250  | 175  | -    | -    | -    | 200  | 250  | 175  |
| Locust bean gum           | 200  | 150  | 225  | -    | -    | -    | -    | -    | -    |
| Tamarind gum              | -    | -    | -    | 200  | 150  | 225  | 175  | -    | -    |
| Dammar gum                | -    | -    | -    | 200  | 150  | 225  | 175  | 200  | 150  |

Before compression, the prepared polymer blends were evaluated for flow properties like the angle of repose, bulk density, tapped density, Carr’s index, and Hausner’s ratio. The core tablets were press-coated with 400mg of prepared barrier blend as per the mentioned formulae from Z1F9 to Z9F9. 200mg of barrier layer material was weighed and transferred into a 10mm die and then the core tablet was placed manually at the center. The remaining 200mg of the barrier layer material was added into the die and compressed.

2.2.5 Evaluation of Solid Dispersions

a) Drug entrapment efficiency [13]

The drug content in the solid dispersion was determined spectrophotometrically. An accurately weighed sample of solid dispersion equivalent to 10 mg of Zafirlukast was dissolved in 10 ml of acetone. The solution was filtered, suitably diluted with distilled water with 0.5% SLS and the absorbance was measured at 230 nm. The drug content was calculated from the calibration curve and expressed as percent entrapment efficiency as explained in the equation below-

\[
\text{Entrapment efficiency} = \left( \frac{\text{Actual drug loading}}{\text{Theoretical drug loading}} \right) \times 100
\]

b) In vitro dissolution studies [14]:

Dissolution studies of pure drug and all the solid dispersions of Zafirlukast were carried out using USP type II dissolution apparatus (paddle type) by using 900ml of distilled water with 0.5% SLS as the dissolution medium at a speed of 50rpm and a temperature of 37±0.5°C. 5ml samples were withdrawn through a filter of 0.45μm at different time intervals, suitably diluted, and assayed for Zafirlukast by measuring absorbance at 230 nm.

2.2.6 Evaluation of Core Tablets [14,15,16]

All the prepared core tablets were optimized by average weight, hardness, friability, thickness, drug content, disintegration time, wetting time, and in vitro dissolution for further conversion of selected core tablet in the form of compression-coated tablets of Zafirlukast.

2.2.6.1 Average weight

Average weight was carried out for 20 tablets selected at random from the batch containing 100 tablets. The results are given in Table: 7.

2.2.6.2 Hardness

Hardness was determined by Monsanto hardness tester.
2.2.6.3 Friability
The friability of 20 tablets was determined by Roche friabilator at 25 rpm for 4 min.

2.2.6.4 Thickness
Thickness was measured by vernier calipers.

2.2.6.5 Drug content
Drug content was determined by weighing and grinding 10 randomly selected tablets and dissolving powder equivalent to 10 mg of the drug in 100 ml of distilled water with 0.5% SLS. The solution was then sonicated for 5 min and then filtered through a 0.45μm membrane filter. The absorbance of this solution was determined at 230 nm and drug content was calculated.

2.2.6.6 Disintegration time
The in vitro disintegration studies were carried out using a digital tablet disintegration test apparatus. One tablet was placed in each of the 6 tubes of the basket assembly and then a disk was added to each tube. This assembly was then suspended in a 1-liter beaker containing water with its temperature being maintained at 37±2°C. The basket was then moved up and down through a distance of 5 to 6 cm, at the frequency of 28 to 32 cycles per minute. The time required for the complete disintegration of the tablet was recorded. It is expressed in seconds.

2.2.6.7 In vitro dissolution rate studies
In vitro release rate studies of the pressed tablets were performed using the USP type II apparatus (paddle type) by using 900 ml of distilled water with 0.5% SLS as the dissolution medium at a speed of 50 rpm and a temperature of 37±0.5°C. 5 ml samples were withdrawn through a filter of 0.45μm for every hour up to 10 hours and the lag time was observed for every batch of tablets. The withdrawn samples were analyzed spectrophotometrically by measuring the absorbance at 230 nm.

3. RESULTS AND DISCUSSION

3.1 Drug-Excipient Interaction Studies
The FTIR spectrum of Zafirlukast sodium exhibited a peak at 3443.98 cm⁻¹ due to N-H stretching and at 1616.51 cm⁻¹ due to SO₂ stretching.

There was no interference of the functional group as the principal peaks of the Zafirlukast were found to be unaltered in the final optimized formulation, indicating they were compatible chemically.

3.2 Evaluation of Solid Dispersions

3.2.1 Drug entrapment efficiency
From the drug entrapment values it was observed that solid dispersions prepared with the solvent evaporation method were better entrapped compared to physical mixing and kneading methods.

3.2.2 In vitro drug release studies
All the solid dispersions of Zafirlukast were subjected to in vitro drug release studies to
select the optimized formulation possessing an increased in-vitro dissolution rate. The dissolution profiles of Zaf: PEG 15000 solid dispersions were shown in Fig. 3, 4 and 5. The dissolution rate of Zafirlukast was found to be increased in all the solid dispersions prepared by physical mixing, kneading, and solvent evaporation methods in comparison to the dissolution rate of pure drug. The solid dispersions prepared by the solvent evaporation method exhibited better dissolution profiles than those prepared by physical mixing and kneading methods. Amongst all the solid dispersions of Zafirlukast, the formulation PF15 prepared by the solvent evaporation method in Zaf: polymer ratio of 1:2.5 was found to possess the highest dissolution rate of 95.69% in 60 min (Fig. 5). The increased dissolution rate may be due to the higher solubility of PEG 15000 in the dissolution medium and the better wettability of Zafirlukast in the conjugate.

3.3 Evaluation of Immediate Release Core Tablets

3.3.1 Pre-compression parameters

Powder blends used for preparing immediate release core tablets (ZF’s) were evaluated for angle of repose, bulk density, tapped density, Hausner’s ratio, Carr's index, The values for the angle of repose, Hausner's ratio, and compressibility index were found to be in good correlation, indicating that all the formulations possess passable flow property and compressibility.

Table 4. Drug Entrapment efficiency values

| Formulation Code | Entrapment efficiency |
|------------------|-----------------------|
| PF1              | 52.5                  |
| PF2              | 52.6                  |
| PF3              | 52.8                  |
| PF4              | 53.14                 |
| PF5              | 54.68                 |
| PF6              | 76.33                 |
| PF7              | 83.84                 |
| PF8              | 85.02                 |
| PF9              | 89.76                 |
| PF10             | 91.35                 |
| PF11             | 63.69                 |
| PF12             | 71.22                 |
| PF13             | 78.01                 |
| PF14             | 88.16                 |
| PF15             | 93.45                 |

Fig. 1. FTIR of Zafirlukast (Pure Drug)
Fig. 2. FTIR of Optimized Formulation (Z9F9)

Fig. 3. Dissolution profiles of solid dispersions prepared by Physical mixing

Fig. 4. Dissolution profiles of solid dispersions prepared by Kneading method
Table 5. Cumulative percentage drug release of solid dispersions prepared using PEG 15000

| Time (min) | Pure Drug | PF1 | PF2 | PF3 | PF4 | PF5 | PF6 | PF7 | PF8 | PF9 | PF10 | PF11 | PF12 | PF13 | PF14 | PF15 |
|------------|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|------|------|
| 0          | 0         | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0    | 0    | 0    | 0    | 0    | 0    |
| 15         | 6.5       | 3.45| 3.86| 4.25| 5.84| 6.47| 16.32| 19.87| 22.3| 25.12| 28.7 | 28.78| 30.12| 34.9 | 38.77| 45.08|
| 30         | 12.6      | 12.36| 13.01| 13.98| 14.76| 16.01| 31.1| 35.66| 40.12| 44.76| 49.25| 42.11| 46.88| 51.17| 56.6 | 62.63|
| 45         | 16.4      | 22.19| 23.11| 24.26| 25.97| 26.73| 43.6| 47.78| 59.98| 68.23| 79.19| 53.55| 59.6 | 64.4 | 71.57| 80.01|
| 60         | 19.1      | 28.07| 29.26| 31.08| 32.58| 33.94| 55.56| 62.08| 72.35| 81.54| 91.24| 68.45| 73.58| 78.5 | 86.5 | 95.69|

Table 6. Pre-compression evaluation parameters

| F.No | Bulk density (g/ml) | Tapped density (g/ml) | Carr’s index (%) | Hausner’s ratio | Angle of repose (θ) |
|------|---------------------|-----------------------|------------------|-----------------|---------------------|
| ZF1  | 0.361               | 0.431                 | 16.24            | 1.19            | 24.15              |
| ZF2  | 0.345               | 0.410                 | 15.85            | 1.19            | 23.69              |
| ZF3  | 0.341               | 0.413                 | 17.43            | 1.21            | 24.13              |
| ZF4  | 0.369               | 0.436                 | 15.36            | 1.18            | 25.65              |
| ZF5  | 0.357               | 0.429                 | 16.78            | 1.20            | 24.78              |
| ZF6  | 0.361               | 0.411                 | 12.17            | 1.14            | 28.01              |
| ZF7  | 0.358               | 0.423                 | 15.37            | 1.18            | 26.64              |
| ZF8  | 0.360               | 0.435                 | 17.24            | 1.21            | 25.45              |
| ZF9  | 0.374               | 0.442                 | 15.39            | 1.18            | 22.12              |

Table 7. Evaluation of post-compression parameters

| Formulation | Weight variation (mg) | Hardness (kg/cm²) | Thickness (mm) | Friability (%) | Disintegration time (sec) | Drug content (%) | Wetting time (sec) |
|-------------|-----------------------|-------------------|---------------|----------------|--------------------------|------------------|-------------------|
| ZF1         | 98.78                 | 5.1              | 4.23          | 0.23           | 121                      | 96.41            | 36                |
| ZF2         | 99.15                 | 5.2              | 4.30          | 0.13           | 116                      | 95.46            | 35                |
| ZF3         | 99.45                 | 5.3              | 4.16          | 0.56           | 97                       | 97.18            | 32                |
| ZF4         | 98.86                 | 5.4              | 4.10          | 0.47           | 109                      | 96.50            | 31                |
| ZF5         | 99.16                 | 5.1              | 4.34          | 0.78           | 90                       | 97.71            | 30                |
| ZF6         | 98.79                 | 5.3              | 4.42          | 0.69           | 72                       | 98.78            | 34                |
| ZF7         | 99.66                 | 5.5              | 4.50          | 0.28           | 89                       | 98.80            | 28                |
| ZF8         | 99.47                 | 5.2              | 4.13          | 0.09           | 74                       | 99.15            | 28                |
| ZF9         | 99.59                 | 5.3              | 4.27          | 0.13           | 58                       | 99.45            | 23                |
3.3.2 Post-Compression Parameters

The prepared core tablets were evaluated, and were found to exhibit satisfactory tablet characteristics as shown in Table 7 and 8. The drug content of all the formulations was found to exist between 90 and 100% and formulation ZF9 was found to be within the USP limits as per the drug content. The in vitro disintegration time and wetting time were found to be very less for ZF9 formulation that is 58 seconds and 23 seconds respectively and this batch tablets have also shown better dissolution profile (99.85% drug release in 25 minutes) when compared to remaining formulations. Hence, it was optimized as the best immediate release core tablet formulation for the burst release of the drug. The results of the dissolution profiles of all the formulations (ZF1-ZF9) were represented graphically in Fig. 6.

3.4 Evaluation of Compression-coated Tablets

3.4.1 Evaluation of polymer layer blends

The polymer layer blends of all the compression-coated tablet formulations (Z1F9-Z9F9) were evaluated for flow properties and it was found that the flow property of the prepared polymer
layer blend of Z4F9 and Z5F9 was good, that of Z1F9 and Z2F9 was fair, Z3F9, Z8F9, and Z9F9 have passable flow properties whereas the flowability of remaining blends was poor.

3.4.2 Evaluation of compression-coated tablets

The prepared compression-coated tablets were evaluated for all the post-compression parameters and were found to exhibit satisfactory tablet characteristics. The swelling index was found to be maximum at the 5th hour for the formulation Z9F9. The results were tabulated in Table: 10 and 11.

Table 8. In vitro Drug Release Studies

| Time (min) | ZF1 | ZF2 | ZF3 | ZF4 | ZF5 | ZF6 | ZF7 | ZF8 | ZF9 |
|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0         | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| 5         | 12.11 | 15.54 | 18.08 | 16.52 | 18.65 | 21.14 | 19.97 | 22.30 | 25.89 |
| 10        | 20.03 | 23.36 | 26.67 | 26.68 | 27.70 | 30.09 | 29.70 | 31.32 | 34.21 |
| 15        | 42.16 | 46.55 | 52.02 | 45.50 | 50.16 | 58.77 | 54.16 | 58.79 | 65.12 |
| 20        | 55.49 | 59.80 | 68.72 | 68.81 | 72.69 | 76.59 | 72.30 | 80.23 | 97.15 |
| 25        | 64.77 | 69.91 | 76.82 | 80.05 | 84.40 | 88.14 | 85.59 | 96.65 | 99.85 |
| 30        | 76.48 | 80.22 | 85.15 | 91.13 | 93.17 | 98.79 | 99.36 | 99.48 | -    |
| 35        | 85.50 | 89.77 | 92.20 | 99.66 | 97.78 | 99.56 | -    | -    | -    |
| 40        | 91.17 | 95.59 | 98.84 | -   | 99.32 | -    | -    | -    | -    |
| 45        | 96.69 | 100.03 | 99.7 | -   | -    | -    | -    | -    | -    |

Table 9. Polymer layer blend evaluation parameters

| F.No | Angle of repose (θ) | Bulk density (g/ml) | Tapped density (g/ml) | Carr’s index (%) | Hausner’s ratio |
|------|---------------------|---------------------|-----------------------|------------------|-----------------|
| Z1F9 | 36.14               | 0.42                | 0.51                  | 17.65            | 1.21            |
| Z2F9 | 39.56               | 0.41                | 0.50                  | 18               | 1.22            |
| Z3F9 | 42.09               | 0.39                | 0.49                  | 20.41            | 1.26            |
| Z4F9 | 35.64               | 0.43                | 0.49                  | 12.24            | 1.14            |
| Z5F9 | 32.03               | 0.44                | 0.52                  | 15.38            | 1.18            |
| Z6F9 | 51.27               | 0.33                | 0.46                  | 28.26            | 1.39            |
| Z7F9 | 46.13               | 0.41                | 0.57                  | 28.07            | 1.39            |
| Z8F9 | 41.75               | 0.39                | 0.51                  | 23.53            | 1.31            |
| Z9F9 | 43.46               | 0.32                | 0.41                  | 21.95            | 1.28            |

Table 10. Evaluation of Compression-coated tablet parameters

| Form code | Hardness (kg/cm²) | Thickness (mm) | Weight variation (mg) | Friability (%) |
|----------|------------------|---------------|-----------------------|----------------|
| Z1F9     | 7.1              | 6.85          | 498.80                | 0.80           |
| Z2F9     | 7.6              | 6.56          | 499.99                | 0.97           |
| Z3F9     | 8.1              | 7.02          | 499.16                | 0.64           |
| Z4F9     | 7.9              | 6.93          | 497.86                | 0.71           |
| Z5F9     | 8.2              | 7.05          | 501.08                | 0.55           |
| Z6F9     | 8.2              | 7.01          | 499.86                | 0.61           |
| Z7F9     | 8.5              | 6.99          | 497.99                | 0.72           |
| Z8F9     | 8.9              | 7.16          | 500.46                | 0.09           |
| Z9F9     | 8.7              | 7.05          | 499.54                | 0.36           |
Table 11. % Swelling index values

| Time (hrs) | Z1F9 | Z2F9 | Z3F9 | Z4F9 | Z5F9 | Z6F9 | Z7F9 | Z8F9 | Z9F9 |
|-----------|------|------|------|------|------|------|------|------|------|
| 0         | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 1         | 142  | 118  | 149  | 96   | 108  | 146  | 154  | 125  | 144  |
| 2         | 146  | 156  | 164  | 118  | 114  | 168  | 176  | 154  | 178  |
| 3         | 164  | 164  | 202  | 124  | 126  | 196  | 208  | 174  | 224  |
| 4         | 189  | 178  | 228  | 132  | 148  | 214  | 225  | 206  | 262  |
| 5         | 216  | 184  | 242  | 148  | 172  | 232  | 246  | 229  | 296  |
| 6         | 184  | 172  | 216  | 126  | 158  | 184  | 215  | 198  | 174  |
| 7         | 168  | 146  | 194  | 114  | 122  | 162  | 184  | 158  | 155  |
| 8         | 141  | 128  | 188  | 92   | 105  | 139  | 159  | 132  | 116  |
| 9         | 115  | 106  | 146  | 76   | 98   | 114  | 122  | 102  | 98   |

Table 12. In vitro Drug release studies

| Time (hrs) | Z1F9 | Z2F9 | Z3F9 | Z4F9 | Z5F9 | Z6F9 | Z7F9 | Z8F9 | Z9F9 |
|-----------|------|------|------|------|------|------|------|------|------|
| 0         | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 1         | 0.54 | 0.41 | 0.18 | 0.89 | 0.51 | 0.55 | 0.28 | 0.41 | 0.22 |
| 2         | 0.63 | 0.97 | 0.94 | 1.36 | 0.77 | 1.23 | 0.56 | 0.77 | 0.64 |
| 3         | 2.03 | 1.75 | 1.22 | 4.47 | 3.69 | 5.60 | 2.81 | 3.69 | 0.84 |
| 4         | 4.12 | 2.98 | 5.07 | 9.98 | 8.79 | 10.23| 9.24 | 8.79 | 1.97 |
| 5         | 19.65| 13.69| 25.18| 26.6 | 26.65| 21.36| 26.65| 26.65| 13.36|
| 6         | 32.30| 38.79| 79.02| 47.48| 48.87| 34.45| 48.87| 48.87| 74.46|
| 7         | 44.47| 52.65| 99.97| 69.14| 66.30| 66.54| 66.30| 66.30| 85.97|
| 8         | 74.12| 68.78| -    | 87.19| 87.90| 80.21| 87.90| 87.90| 98.89|
| 9         | 84.20| 79.96| -    | 95.24| 99.02| 96.54| 99.86| 92.64 | -    |
| 10        | 98.46| 92.64| -    | 100.01| -    | 98.26 | -    | 96.22 | -    |

Fig. 7. Drug release profiles of compression-coated tablets (Z1F9-Z9F9)

4. CONCLUSION

Compression coated tablets of Zafirlukast for chronotherapeutic delivery were developed successfully using natural polymers. FT-IR studies also revealed that there was no chemical interaction between the drug and polymers used in the optimized formulation (Z9F9). Various
parameters such as drug entrapment efficiency, flow properties, hardness, friability, weight variation, drug content, wetting time, swelling index, *in vitro* drug release rate were evaluated for all the formulations. The formulation Z9F9 containing xanthan gum and dammar gum as the barrier layer for retarding the release of the drug from the tablet was found to exhibit the results which are consistent with the demands of chronotherapeutic drug delivery. In conclusion, it can be suggested that the combination of xanthan gum and dammar gum in the optimized composition could be promising in achieving chronotherapeutic benefits in asthma patients.

**DISCLAIMER**

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

**CONSENT**

It is not applicable.

**ETHICAL APPROVAL**

It is not applicable.

**ACKNOWLEDGEMENTS**

The authors are thankful to Institute of Pharmaceutical Technology, Sri Padmavathi Mahila Visvavidyalayam, Tirupati for providing necessary facilities to carry out the research work.

**COMPETING INTERESTS**

Authors have declared that no competing interests exist.

**REFERENCES**

1. Chien YW. Novel Drug Delivery Systems, Ilnd edition, Revised and expanded, Marcel Dekker, New York, 1992, 139-140.
2. Youan BIBC. Chronopharmaceutics: Science and Technology for Biological Rhythm-Guided Therapy and Prevention of Diseases. John Wiley & Sons, Inc. 1-37.
3. Rajendra Awasthi. Chronotherapy: Science and Technology of drug scheduling on the basis of Biological rhythm. Journal of Chronotherapy and Drug Delivery. 2010;1(1).
4. Vivek Kumarpawar. Chronotherapy: An approach to synchronize drug delivery with circadian rhythm. Journal of Chronotherapy and Drug Delivery. 2010;1(1):1-8.
5. Bailpattar Padmaxi, Karwa Preeti, Patel Kirtan, Mondal Md. Sahidullah, Pasha Mohamed Irshad. Formulation And Evaluation Of Time Controlled Drug Delivery System Of Montelukast Sodium. International Journal of Pharmaceutical Innovations. 2012;2(3):1-12.
6. Latha K, Uhumwangho MU, Sunil SA, Srikanth MV, Ramana Murthy KV. Preparation and In Vitro Evaluation of Compression Coated Tablet of Losartan Potassium Using Admixture of Hydrophilic Polymer and Excipients”, Int J Novel Drug Deliv Tech 2011;1(1):29-39.
7. Sarfaraz Md, Prasad Y, Reddy SR, Doddayya H, Udupi RH. Development and Evaluation of Press Coated Time-Release Tablet of Nifedipine”, Asian J. Pharm. Res. 2011;1(3):58-63.
8. Martain RJS. Chronobiology of asthma”, Am.J.Resir.Crit.Care Med. 158(1988)1002-1007.
9. https://pubchem.ncbi.nlm.nih.gov/compound/Zafirlukast.
10. Leuner C, Dressman J., “Improving drug solubility for oral delivery using solid dispersions”, Eur J Pharm Biopharm 2000:50: 47–60.
11. https://www.shimadzu.com/an/service-support/technical-support/analysis-basics/ftirtalk/talk8.html.
12. Bandela JJ, Anupama CH, “Advanced PEGylation for the Development of Raloxifene Hydrochloride, BCS Class II Drug. J Young Pharm. 2009;1(4):295-300.
13. Radha Madhavi B, Kanaka Durga Devi N, Prameela Rani A. Preparation and Characterization of Zafirlukast-B-cyclodextrin Complexes using Solid Dispersion Techniques”, International Journal of Pharmaceutical Sciences Review and Research. 2010;4(1):Article 016.
14. Sreekanth K, Naresh G, Md Imran, Nagesh K, Hindustan Abdul Anad. Design, Development and Optimization of
Zafirlukast Press Coat Tablets for Pulsatile Drug Delivery. IJMPR, 2014;2(6):834-841.
15. Sasank Bharat Kumar, Kattamuri Ramakotaiah, Mogili Lakshman Potti, Veeranjaneyulu Bandi, Prasada Rao M. Formulation and Evaluation of Zafirlukast Oral Disintegrating Tablets'', International Journal of Universal Pharmacy and Bio Sciences. 2013;2(5):.
16. Lachman L, Lieberman HA, Joseph LK. The Theory and Practice of Industrial Pharmacy, 1990; Third Edition:317-324.

© 2021 Neeharika and Jyothi; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/69874